Mr Alexander Vos joined the Supervisory Board of CiMaas in May 2018. Alexander Vos is the former CEO of PharmaCell BV, based in Maastricht and Geleen.

Pharmacell is the leading Contract Manufacturing Organization (CMO) in Europe for cell therapeutic products. The company was acquired by Lonza in 2017 and is now continuing its activities under the name Lonza Netherlands BV. Mr. Vos has been CEO for 7 years and has expanded the business from 15 to 150 employees through successful collaborations with key players in the cell and gene therapy industry. PharmaCell produced products for European and large American partners for clinical research and, after product approval, for the European market.

Alexander Vos: “CiMaas has an interesting and innovative portfolio of products that can potentially contribute to new treatment methods for patients. I am excited to be able to support the team in this important mission”.

Professor Dr Gerard Bos, CEO of CiMaas: “We welcome the contribution of Alexander Vos to our Supervisory Board. His experience in managing a cell therapy company makes Alexander Vos an extremely valuable partner for CiMaas. His experience and knowledge will have positive consequences for CiMaas for closing agreements with other partners “.